Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting

OBJECTIVE:

To compare achievement of quality goals (HbA1c, weight loss/body mass index [BMI], systolic blood pressure [SBP]), including maintaining HbA1c, between patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin 300 mg (CANA) or a GLP-1 in an actualpractice setting.

METHODS:

Adults with T2DM newly initiated on CANA or a GLP-1 were identified from the IQVIATM Real-World Data Electronic Medical Records-US database (2012Q2-2016Q1). To account for differences in baseline characteristics, inverse probability of treatment weighting was used. Outcomes were compared using Cox models (hazard ratios [HRs] and 95% confidence intervals [CIs]) and Kaplan-Meier analyses.

RESULTS:

CANA (n = 11,435) and GLP-1 (n = 11,582) cohorts had similar attainment of HbA1c < 8.0% 64mmol mol and hba1c>< 9.0% 75mmol mol hba1c>< 8.0%: hr ci=" 0.98" 0.91-1.06 hba1c>< 9.0%: hr ci=" 1.02" 0.93-1.12 while glp-1patientswere 10 more likely to achieve hba1c>< 7.0% 53mmol mol. cana and glp-1patientswere similar in maintaining hba1c>< 7.0%, >< 8.0%, or><9.0%, achieving weight loss 5 hr ci=" 1.05" 0.99-1.12 achieving bmi><30 kg m2hr ci=" 1.11" 0.98-1.27 and achieving sbp><140 mmhg hr ci=" 1.07" 0.98-1.17. canapatientswere 30 less likely to discontinue treatment 28 less likely to have a prescription for a new anti-hyperglycemic and 17-21 less likely to fail to maintain hba1c>< 8.0% or 9.0 or have a prescription for a new anti-hyperglycemic composite outcome vs glp-1. no significant difference was observed for the composite outcome using the hba1c>< 7.0% threshold.>

CONCLUSIONS:

This retrospective study in an actual practice setting showed that CANA patients were generally as likely as GLP-1 patientsto achieve HbA1c, weight, and blood pressure thresholds, and to maintain glycemic control while being less likely to discontinue treatment and/or have a new anti-hyperglycemic prescribed.